

- Bogoch ER. Torsional properties of the rabbit femoral diaphysis: bisphosphonate prevents arthritis-induced loss of fracture toughness. *J Orthop Res* 1995;13:876-80.
12. Pysklywec MW, Bogoch ER, Moran EL, Fornasier VL. Altered pore characteristics and geometry in diaphyseal cortical bone affected by inflammatory arthritis. *J Orthop Rheumatol* 1996;9: 150-6.
13. Hajcsar EE, Roberts EM, Moran EL, Grynpsas M, Bogoch ER. Osteonal parameters in experimental inflammatory arthritis and treatment with zoledronate in rabbits [abstract]. Presented at the annual meeting of the Canadian Orthopaedic Association, Hamilton, Ont., June 1, 1997.
14. Nesbitt SA, Horton MA. Trafficking of matrix collagens through bone-resorbing osteoclasts. *Science* 1997; 276:266-9.
15. Salo J, Lehenkari P, Mulari M, Metsikkö K, Väänänen H. Removal of osteoclast bone resorption products by transcytosis. *Science* 1997;276:270-3.
16. Fleisch H. New bisphosphonates in osteoporosis. *Osteoporos Int* 1993;3 (Suppl 2):S15-22.
17. Bogoch ER, Roberts EM, Moran EL, Fornasier VL. Pamidronate prevents rapid bone remodeling and rapid bone loss in experimental inflammatory arthritis. *Orthop Trans* 1996;19(4): 1110-1.
18. Pysklywec MW, Moran EL, Bogoch ER: Zoledronate (CGP 42 446), a bisphosphonate, protects against metaphyseal intracortical defects in experimental inflammatory arthritis. *J Orthop Res* 1997;15:858-61.
19. Bogoch ER, Moran EL, Roberts EM, Fornasier VL. Bisphosphonate CGP 42 446 reduces cartilage destruction in experimental inflammatory arthritis [abstract]. Presented at the annual meeting of the Canadian Orthopaedic Research Society, Quebec, May 25, 1996.
20. van der Sluijs JA, Geesink RG, van der Linden AJ, Bulstra SK, Kuyer R, Drukker J. The reliability of the Mankin score for osteoarthritis. *J Orthop Res* 1992;10(1):58-61.
21. Fornasier VL, Moran EL, Bogoch ER. The bisphosphonate zoledronate modifies the intraosseous response of cell populations in experimental inflammatory arthritis (EIA). Presented at the annual meeting of the American Society of Bone & Mineral Research, Hamilton, Ont., June 1, 1997.

## SESAP Question / Question SESAP

### ITEM 482

A 32-year-old woman has muscle weakness. The chest computed tomogram (CT) shown is obtained. Which of the following statements about her condition is NOT true?

- (A) Her weakness is likely to improve after treatment with neostigmine, azathioprine, or corticosteroids
- (B) It is most likely to be malignant
- (C) It may be associated with Cushing's syndrome, RBC aplasia, hypoproteinemia, and collagen vascular disease
- (D) Operation is indicated in this patient
- (E) The condition is associated with antibodies to acetylcholine receptors in the muscle



For the critique of item 482 see page 282.

(Reproduced by permission from *SESAP '96-'98 Syllabus Surgical Education and Self-Assessment Program*, Volume 2, 9th edition. For enrolment in the Surgical Education and Self-Assessment Program, please apply to the American College of Surgeons, 55 East Erie St., Chicago, IL 60611, USA.)